Literature DB >> 28270270

A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.

Chelsey Edmonds, Michael Swanoski.   

Abstract

Geriatric patients often experience insomnia because of physiological and neurological changes that occur during the aging process. Use of benzodiazepines, nonbenzodiazepine hypnotics, and diphenhydramine for the treatment of insomnia pose an increased risk of cognitive impairment, falls, and fractures in this patient population. Therapeutic alternatives approved by the Food and Drug Administration include suvorexant, doxepin, ramelteon, and tasimelteon, which have shown efficacy and safety in various studies. This paper explores and outlines the available safety and efficacy data associated with these medications and reviews their potential place in therapy in treating insomnia in the geriatric population.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28270270     DOI: 10.4140/TCP.n.2017.156

Source DB:  PubMed          Journal:  Consult Pharm        ISSN: 0888-5109


  3 in total

1.  Melatonin receptor agonist ramelteon attenuates mouse acute and chronic ischemic brain injury.

Authors:  Xiao-Li Wu; Shou-Sheng Lu; Meng-Ru Liu; Wei-Dong Tang; Jun-Zi Chen; Yan-Rong Zheng; Anil Ahsan; Ming Cao; Lei Jiang; Wei-Wei Hu; Jia-Ying Wu; Zhong Chen; Xiang-Nan Zhang
Journal:  Acta Pharmacol Sin       Date:  2020-02-27       Impact factor: 6.150

2.  Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington's Disease-Data from a Real World Cohort.

Authors:  Jannis Achenbach; Carsten Saft; Simon Faissner
Journal:  Brain Sci       Date:  2021-03-25

3.  Ramelteon ameliorated 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity in neuronal cells in a mitochondrial-dependent pathway.

Authors:  Chuo Li; Yusheng Zhang; Rongrong Liu; Yuzhen Mai
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.